Country selection
To offer the best possible experience tailored to your national regulatory requirements and the available product portfolio, please choose your country from the following list. This option will be saved throughout the browser session. Thank you!
User experience & privacy
We use cookies to offer you an optimal website experience. This includes cookies necessary for the operation of the website and for the control of our commercial corporate goals, as well as those only used for anonymous statistical purposes, comfort settings or to display personalized content. Please note that based on your settings, not all functions of the website may be available. To find out more, please refer to our Data Privacy Statement.

Lutetium-177 (n.c.a.)

Radiochemical for non-clinical research purposes

Eckert & Ziegler Radiopharma GmbH offers non-carrier-added [177Lu]Lutetium Chloride solution for your research activities. The radiochemical solution is used for the preparation of radiolabeled compounds in the non-clinical research context.

Lutetium-177 n.c.a is currently only available in non-GMP research grade. Our teams are working on the provision of GMP grade [177Lu]Lutetium Chloride solution. Use the contact form at the end of the page to get in touch and find out more.

Detail Information

Lutetium-177 is a β-emitter with a half-life of 6.65 days. It can be produced via two different routes, direct by irradiation of Lutetium-176 for carrier-added or indirect by irradiation of Ytterbium-176 for non-carrier-added form. Lutetium-177 decays by emission of beta radiation (β: Emax= 498 keV) and gamma radiation (γ: 208 keV – 10.3 % abundance) to Hafnium-177.

Lutetium-177 has become more and more important over the last years as a substance used in many new radiopharmaceuticals, especially for cancer therapy. In combination with diagnostic [68Ga]-based-agents it is now the main therapeutic nuclide for theranostic approaches such as with DOTA-conjugated compounds for binding on the prostate specific membrane antigen (PSMA). A large number of further radiotherapeutic agents are currently under development for several types of cancer.

Method and Specifications
Eckert & Ziegler offers Lutetium-177 in high quality no-carrier-added (n.c.a.) form. [177Lu]Lutetium Chloride Solution is produced by irradiation of Ytterbium-176 ([176Yb]) and subsequent separation of [177Lu] in our radiochemical facility. This process achieves highest purity.


Table - Eckert & Ziegler Lu-177 Chloride Solution Specifications

Shipping and Calibration
Eckert & Ziegler offers high flexibility regarding calibration time and date. A pre-calibration up to seven days is possible.
Lutetium-177 will be delivered within four business days worldwide.


Since March 2020, Eckert & Ziegler is supplying [177Lu]Lutetium Chloride solution to selected customers for non-clinical research. We are continuously expanding our production to provide additional batches to further customers. Furthermore, we plan to have Lutetium-177 in GMP quality available in 2021.


Timeline Lu-177


For further information please refer to the specification sheet or contact us through the contact form below.

Eckert & Ziegler Radiopharma offers a wide range of radionuclides for chemical or pharmaceutical use, from Actinium-225 via Gallium-68 to Yttrium-90.


Eckert & Ziegler
Radiopharma GmbH
Robert-Rössle-Straße 10
13125 Berlin
Fax: +49 30 941084 470

Get in touch

Contact us regarding your questions and we will get back to you as soon as possible.
By clicking send, you give your consent for processing your personal data in accordance with our Data Privacy Statement.
Permission required
In order to submit your request it is required to load a 3rd-party service (Google Re-Captcha spam protection system). You current privacy settings prevent this from happening automatically. By clicking the button below you explicitly allow to temporarily (on this page) load 3rd party services.